OBJECTIVE: It has been hypothesized that individuals without dementia with Alzheimer disease (AD) neuropathology may be in the preclinical stages of dementia and could be experiencing subtle cognitive decline. The purpose of this study was to compare longitudinal cognitive performance in oldest-old individuals without dementia with and without AD neuropathology. METHODS: The study included 58 individuals without dementia from The 90+ Autopsy Study, a population-based study of aging and dementia in individuals aged 90 and older. Participants had neurologic and neuropsychological testing every 6 months with an average of 3 years of follow-up. We compared the trajectory of cognitive performance on the Modified Mini-Mental State Examination (3MS) and the California Verbal Learning Test II (CVLT) by level of AD neuropathology. Based on Consortium to Establish a Registry for Alzheimer's Disease plaque staging, individuals were categorized as having low (none or sparse) or high (moderate or frequent) plaques. Based on Braak and Braak staging, participants were classified as having low (stages I-III) or high (IV-VI) tangles. RESULTS: No significant differences were found in 3MS or CVLT cognitive performance over time based on plaque or tangle staging. Both high and low pathology groups showed modest improvements on the 3MS and CVLT consistent with learning effects. CONCLUSIONS: AD neuropathology at autopsy is not associated with the trajectory of cognitive performance in the 3 years before death in oldest-old without dementia. Despite the presence of AD neuropathology at death, oldest-old without dementia display learning effects on cognitive tests. Further research is necessary to understand factors other than AD neuropathology that may affect cognition in the oldest-old.
OBJECTIVE: It has been hypothesized that individuals without dementia with Alzheimer disease (AD) neuropathology may be in the preclinical stages of dementia and could be experiencing subtle cognitive decline. The purpose of this study was to compare longitudinal cognitive performance in oldest-old individuals without dementia with and without AD neuropathology. METHODS: The study included 58 individuals without dementia from The 90+ Autopsy Study, a population-based study of aging and dementia in individuals aged 90 and older. Participants had neurologic and neuropsychological testing every 6 months with an average of 3 years of follow-up. We compared the trajectory of cognitive performance on the Modified Mini-Mental State Examination (3MS) and the California Verbal Learning Test II (CVLT) by level of AD neuropathology. Based on Consortium to Establish a Registry for Alzheimer's Disease plaque staging, individuals were categorized as having low (none or sparse) or high (moderate or frequent) plaques. Based on Braak and Braak staging, participants were classified as having low (stages I-III) or high (IV-VI) tangles. RESULTS: No significant differences were found in 3MS or CVLT cognitive performance over time based on plaque or tangle staging. Both high and low pathology groups showed modest improvements on the 3MS and CVLT consistent with learning effects. CONCLUSIONS:AD neuropathology at autopsy is not associated with the trajectory of cognitive performance in the 3 years before death in oldest-old without dementia. Despite the presence of AD neuropathology at death, oldest-old without dementia display learning effects on cognitive tests. Further research is necessary to understand factors other than AD neuropathology that may affect cognition in the oldest-old.
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: James E Galvin; Kimberly K Powlishta; Kenneth Wilkins; Daniel W McKeel; Chengjie Xiong; Elizabeth Grant; Martha Storandt; John C Morris Journal: Arch Neurol Date: 2005-05
Authors: C M Hulette; K A Welsh-Bohmer; M G Murray; A M Saunders; D C Mash; L M McIntyre Journal: J Neuropathol Exp Neurol Date: 1998-12 Impact factor: 3.685
Authors: C H Kawas; M M Corrada; R Brookmeyer; A Morrison; S M Resnick; A B Zonderman; D Arenberg Journal: Neurology Date: 2003-04-08 Impact factor: 9.910
Authors: H Crystal; D Dickson; P Fuld; D Masur; R Scott; M Mehler; J Masdeu; C Kawas; M Aronson; L Wolfson Journal: Neurology Date: 1988-11 Impact factor: 9.910
Authors: Alberto J Espay; Joaquin A Vizcarra; Luca Marsili; Anthony E Lang; David K Simon; Aristide Merola; Keith A Josephs; Alfonso Fasano; Francesca Morgante; Rodolfo Savica; J Timothy Greenamyre; Franca Cambi; Tritia R Yamasaki; Caroline M Tanner; Ziv Gan-Or; Irene Litvan; Ignacio F Mata; Cyrus P Zabetian; Patrik Brundin; Hubert H Fernandez; David G Standaert; Marcelo A Kauffman; Michael A Schwarzschild; S Pablo Sardi; Todd Sherer; George Perry; James B Leverenz Journal: Neurology Date: 2019-02-12 Impact factor: 9.910
Authors: Mary Ganguli; Ching-Wen Lee; Beth E Snitz; Tiffany F Hughes; Eric McDade; Chung-Chou H Chang Journal: Neurology Date: 2014-12-03 Impact factor: 9.910
Authors: Ilana J Bennett; Dana E Greenia; Pauline Maillard; S Ahmad Sajjadi; Charles DeCarli; Maria M Corrada; Claudia H Kawas Journal: Neurobiol Aging Date: 2017-04-26 Impact factor: 4.673
Authors: Maria Dekhtyar; Kathryn V Papp; Rachel Buckley; Heidi I L Jacobs; Aaron P Schultz; Keith A Johnson; Reisa A Sperling; Dorene M Rentz Journal: Neuropsychologia Date: 2017-05-01 Impact factor: 3.139
Authors: Patricia A Boyle; Robert S Wilson; Lei Yu; Alasdair M Barr; William G Honer; Julie A Schneider; David A Bennett Journal: Ann Neurol Date: 2013-07-10 Impact factor: 10.422
Authors: Ivy N Miller; Jayandra J Himali; Alexa S Beiser; Joanne M Murabito; Sudha Seshadri; Philip A Wolf; Rhoda Au Journal: Exp Aging Res Date: 2015 Impact factor: 1.645